Latest News  

Tofacitinib Shows Early Potential for Treating Dermatomyositis

A proof-of-concept study including 10 patients treated for dermatomyositis with tofacitinib, an FDA-approved drug for RA and psoriatic arthritis, shows strong clinical efficacy… [Read More]

Medicare Changes Could Have Some Patients Paying More for Drugs

(Reuters Health)—A proposed shift in Medicare coverage for medicines administered by doctors may help reduce total drug spending, but a new study suggests it may… [Read More]

Updated ACP Ethics Manual Provides 6-Step Approach to Dilemmas

NEW YORK (Reuters Health)—The 2019 edition of the American College of Physicians (ACP) ethics manual provides a six-step approach to resolving ethical dilemmas and adds… [Read More]

U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation… [Read More]

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab… [Read More]

Intensive Patient Education May Not Be Helpful for Acute Low Back Pain

Education with recommended first-line care may not improve pain outcomes in patients with acute low back pain. When comparing patients who received education with those who received professional consultation without information or advice, researchers found patient education was no more effective than placebo at reducing depression or incidence of chronic low back pain… [Read More]

View More Latest News »